SLC5A2 and cardiovascular disorder: For instance, a large network meta-analysis showed that SGLT-2 inhibitors reduced hospitalization for HF and renal composite outcome more than GLP-1RA [15], and that in patients with cardiovascular disease, SGLT-2 inhibitors show significant reduction in both heart failure (HF) hospitalizations and mortality for patients with HF and reduced ejection fraction [16].